These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37799473)

  • 1. Corrigendum: Effects of alkalization therapy on hepatocellular carcinoma: a retrospective study.
    Isowa M; Hamaguchi R; Narui R; Morikawa H; Wada H
    Front Oncol; 2023; 13():1291026. PubMed ID: 37799473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alkalization therapy on hepatocellular carcinoma: a retrospective study.
    Isowa M; Hamaguchi R; Narui R; Morikawa H; Wada H
    Front Oncol; 2023; 13():1179049. PubMed ID: 37313464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum: Identification of Mitochondrial-Related Prognostic Biomarkers Associated With Primary Bile Acid Biosynthesis and Tumor Microenvironment of Hepatocellular Carcinoma.
    Zhang T; Nie Y; Gu J; Cai K; Chen X; Li H; Wang J
    Front Oncol; 2021; 11():843623. PubMed ID: 35111689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: C-reactive protein is an indicator of the immunosuppressive microenvironment fostered by myeloid cells in hepatocellular carcinoma.
    Wang Y; Li Z; Huang Z; Yu X; Zheng L; Xu J
    Front Oncol; 2023; 13():1280727. PubMed ID: 37941560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma.
    Che L; Paliogiannis P; Cigliano A; Pilo MG; Chen X; Calvisi DF
    Front Oncol; 2022; 12():874053. PubMed ID: 35494002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of Alkalization Therapy for the Management of Metastatic Pancreatic Cancer: A Retrospective Study.
    Isowa M; Hamaguchi R; Narui R; Morikawa H; Okamoto T; Wada H
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma.
    Xie S; Wang M; Zeng C; Ou Y; Zhao L; Wang D; Chen L; Kong F; Yi D
    Front Oncol; 2023; 13():1338060. PubMed ID: 38162493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellular carcinoma.
    Lei Y; Wang X; Sun H; Fu Y; Tian Y; Yang L; Wang J; Xia F
    Front Oncol; 2024; 14():1438731. PubMed ID: 39050582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum: Fat fraction quantification with MRI estimates tumor proliferation of hepatocellular carcinoma.
    Huang M; Zhang F; Li Z; Luo Y; Li J; Wang Z; Ma L; Chen G; Hu X
    Front Oncol; 2024; 14():1418905. PubMed ID: 38841171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Alkalization Therapy on Chemotherapy Outcomes in Advanced Pancreatic Cancer: A Retrospective Case-Control Study.
    Hamaguchi R; Ito T; Narui R; Morikawa H; Uemoto S; Wada H
    In Vivo; 2020; 34(5):2623-2629. PubMed ID: 32871792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum: Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma.
    Han C; Chen J; Huang J; Zhu R; Zeng J; Yu H; He Z
    Front Oncol; 2023; 13():1162375. PubMed ID: 36969048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum: YY1 Promotes Endothelial Cell-Dependent Tumor Angiogenesis in Hepatocellular Carcinoma by Transcriptionally Activating VEGFA.
    Yang W; Li Z; Qin R; Wang X; An H; Wang Y; Zhu Y; Liu Y; Cai S; Chen S; Sun T; Meng J; Yang C
    Front Oncol; 2021; 11():828861. PubMed ID: 35096629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrigendum: SPOCK1 promotes the development of hepatocellular carcinoma.
    Váncza L; Karászi K; Péterfia B; Turiák L; Dezső K; Sebestyén A; Reszegi A; Petővári G; Kiss A; Schaff Z; Baghy K; Kovalszky I
    Front Oncol; 2023; 13():1203745. PubMed ID: 37152016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis
    Wen J; Aili A; Yan YX; Lai Y; Niu S; He S; Zhang X; Zhang G; Li J
    Front Oncol; 2022; 12():1038279. PubMed ID: 36387066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Machine learning prediction model for post- hepatectomy liver failure in hepatocellular carcinoma: a multicenter study.
    Wang J; Zheng T; Liao Y; Geng S; Li J; Zhang Z; Shang D; Liu C; Yu P; Huang Y; Liu C; Liu Y; Liu S; Wang M; Liu D; Miao H; Li S; Zhang B; Huang A; Zhang Y; Qi X; Chen S
    Front Oncol; 2023; 13():1278295. PubMed ID: 37719010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum: Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma.
    Zhang K; Liu H; Yu M; Zhao H; Yang N; Bi X; Sun L; Lin R; Lü G
    Front Oncol; 2021; 11():785394. PubMed ID: 34722323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Hu X; Bao M; Huang J; Zhou L; Zheng S
    Front Oncol; 2020; 10():617539. PubMed ID: 33330112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: CDT1 is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.
    Cai C; Zhang Y; Hu X; Hu W; Yang S; Qiu H; Chu T
    Front Oncol; 2021; 11():801970. PubMed ID: 34900749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy.
    Li Q; Ma F; Wang JF
    Front Oncol; 2024; 14():1431058. PubMed ID: 38915365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum: ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma.
    Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
    Front Oncol; 2022; 12():979968. PubMed ID: 36072794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.